Back to top

oncology-screening: Archive

Zacks Equity Research

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.

CRMDNegative Net Change ARVNPositive Net Change IMCRNegative Net Change RXRXPositive Net Change

Zacks Equity Research

Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?

RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.

ZTSNegative Net Change ACADNegative Net Change RXRXPositive Net Change

Shaun Pruitt

3 Medical Stocks to Consider as Markets Take a Breather

These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.

JNJPositive Net Change THCPositive Net Change CVSNegative Net Change

Shaun Pruitt

2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL

Investors looking for a momentum stock that could be in store for higher highs may want to consider Celestica (CLS), while those looking for a buy-the-dip target have an intriguing option with Exelixis (EXEL).

EXELNegative Net Change CLSNegative Net Change

Ahan Chakraborty

Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?

Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.

AZNNegative Net Change BMYNegative Net Change MRKNegative Net Change MRNAPositive Net Change ABBVNegative Net Change